Pharmaceuticals, Biotechnology and Life Sciences
hVIVO has signed a contract with Inhalon Biopharma to assess its inhaled IN-002 antiviral candidate (“IN-002”) using the hVIVO Respiratory Syncytial Virus (RSV) Human Challenge Model.
hVIVO has signed a £6.3m contract with a biotechnology client to test its antiviral candidate using the hVIVO Human Rhinovirus (HRV – common cold virus) Human Challenge Study Model.
PrEP Biopharm’s study of its drug, earlier confirmed helpful for influenza and human rhinoviruse (HRV), has been undertaken to test its efficacy of the people with asthma, and check for different dosage, showed varying results.